A Phase I/II Pilot Study Of Intranodal Delivery Of A Plasmid DNA (Synchrovax SEM Vaccine) In Stage IV Melanoma Patients.
Phase of Trial: Phase I/II
Latest Information Update: 21 Jul 2009
At a glance
- Drugs MKC 1106-MT (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors MannKind Corporation
- 21 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Oct 2005 New trial record.